Recurrent B Acute Lymphoblastic Leukemia Not Yet Recruiting Phase 1 / 2 Trials for Inotuzumab ozogamicin (DB05889)

IndicationStatusPhase
DBCOND0107328 (Recurrent B Acute Lymphoblastic Leukemia)Not Yet Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03851081Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaTreatment